Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...
Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, ...
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials; pulmonary fibrosis is a very serious disease, with a life prognosis ...
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
AI-based imaging tools have shown potential in detecting treatment responses in IPF, supporting the use of ENV-101 and AI imaging as trial endpoints. The forced oscillation technique (FOT) may enhance ...
Hosted on MSN
Pulmonary fibrosis: Nerandomilast inhibits phosphodiesterase 4B, may treat multiple forms of disease
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jeffrey J. Swigris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results